People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Serimmune Inc. | — | Biotechnology | Series A | $27.5M | $83.5M | 2023 |
Kirstin Loomis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kirstin Loomis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nicholas Naclerio | 1 | 5 |
| Noah Nasser | 1 | 3 |
| Malek Faham | 1 | 3 |
| Kristin Loomis | 1 | 2 |
| Stephen M. Kujawa | 1 | 1 |
| Kristin M. Loomis | 1 | 1 |
| Nicholas M. Naclerio | 1 | 1 |
| Jaymie R. Sawyer | 1 | 1 |
| John M. Shon | 1 | 1 |
| Bill M. Welch | 1 | 1 |
| Nick Naclerio | 1 | 1 |
| Bill Welch | 1 | 1 |
| Patrick Daugherty | 1 | 1 |
| John Shon | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.